Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
Healthcare
$7.01 -3.62%
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
52W Low $3.65High $10.99
Volume 0.67M
Average 0.85M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$75.37M
FY 2025 · Annual
Investing Cash Flow
$43.38M
FY 2025 · Annual
-54.6% YoYFinancing Cash Flow
$30.05M
FY 2025 · Annual
-27.8% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (124.09M) | (165.29M) | (143.1M) | (76.42M) | (196.04M) |
| Depreciation & Amortization | 789K | 621K | 530K | 340K | (114K) |
| Deferred Income Tax | 1.45M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 29.78M | 35.4M | 21.71M | 18.43M | 14.05M |
| Change in Working Capital | (23.19M) | (19.99M) | 31.42M | (302K) | 28.27M |
| Accounts Receivables | (9.62M) | (5.08M) | 20.12M | (3.8M) | 4.59M |
| Inventory | (1.46M) | (118K) | 1.18M | (1.7M) | 701K |
| Accounts Payables | (2.85M) | 1.17M | 350K | 1.98M | (1.1M) |
| Other Working Capital | (9.26M) | (15.96M) | 9.76M | 3.21M | 24.09M |
| Other Non-Cash Items | 8.14M | (294K) | (3.28M) | (69.53M) | 78.46M |
| Operating Cash Flow | (107.12M) | (149.55M) | (92.72M) | (127.49M) | (75.37M) |
| Capital Expenditures | (5.71M) | (118K) | 0 | (142K) | 0 |
| Acquisitions (Net) | 5.5M | 104.26M | 0 | 0 | 0 |
| Purchases of Investments | (45.23M) | (226.02M) | (159.15M) | (58.82M) | 0 |
| Sales of Investments | 192.78M | 121.88M | 167.09M | 154.44M | 43.38M |
| Other Investing Activities | (5.5M) | (104.26M) | 0 | 0 | 0 |
| Investing Cash Flow | 141.84M | (104.26M) | 7.94M | 95.47M | 43.38M |
| Debt Repayment | 60M | 0 | 0 | 83.3M | 20.54M |
| Common Stock Issued | 9.9M | 189.76M | 1.12M | 1.45M | 9.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.75M | 3.98M | 0 | (43.11M) | 0 |
| Financing Cash Flow | 73.65M | 193.74M | 1.12M | 41.65M | 30.05M |
| Effect of Forex Changes | (48K) | (488K) | (34K) | (11K) | 20K |
| Net Change in Cash | 108.32M | (60.56M) | (83.69M) | 9.62M | (1.92M) |
| Free Cash Flow | (112.83M) | (149.67M) | (92.72M) | (127.63M) | (75.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$196.0M
+ D&A-$114.0K
+ Stock-Based Comp$14.1M
+ Deferred Tax$0
+ Working Capital$28.3M
+ Other Non-Cash$78.5M
= Operating Cash Flow-$75.4M
- Capex$0
= Free Cash Flow-$75.4M
Analysis
FY2025 free cash flow is -$75.4M. FCF conversion is 38.4% of net income. Operating cash flow was -$75.4M, with capex of $0. The largest bridge item is Other Non-Cash at $78.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jul 17, 2026 | |
| SC 13G/A | SC 13G/A filing | Jun 5, 2026 | |
| 8-K | Current report | May 28, 2026 | |
| S-8 | S-8 filing | May 27, 2026 | |
| S-8 | S-8 filing | May 27, 2026 |
Does KPTI generate free cash flow?
Karyopharm Therapeutics Inc. (KPTI) generated -$75.37M of free cash flow in fiscal 2025.
How much operating cash flow does KPTI produce?
Operating cash flow was -$75.37M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.